Target Price | $512.70 |
Price | $417.28 |
Potential | 22.87% |
Number of Estimates | 10 |
10 Analysts have issued a price target IDEXX Laboratories 2025 . The average IDEXX Laboratories target price is $512.70. This is 22.87% higher than the current stock price. The highest price target is $570.00 36.60% , the lowest is $440.00 5.44% . | |
A rating was issued by 15 analysts: 6 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2025 of 22.87% . Most analysts recommend the IDEXX Laboratories stock at Hold. |
10 Analysts have issued a sales forecast IDEXX Laboratories 2024 . The average IDEXX Laboratories sales estimate is $3.9b . This is 0.95% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $3.9b 1.92% , the lowest is $3.9b 0.70% .
This results in the following potential growth metrics:
2023 | $3.7b | 8.72% |
---|---|---|
2024 | $3.9b | 6.02% |
2025 | $4.2b | 7.21% |
2026 | $4.5b | 8.92% |
2027 | $4.8b | 6.35% |
8 Analysts have issued an IDEXX Laboratories EBITDA forecast 2024. The average IDEXX Laboratories EBITDA estimate is $1.3b . This is 4.77% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.4b 11.32% , the lowest is $1.2b 0.25% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $1.2b | 22.17% |
---|---|---|
2024 | $1.3b | 7.44% |
2025 | $1.4b | 10.55% |
2026 | $1.6b | 10.35% |
2027 | $1.8b | 12.06% |
2023 | 32.98% | 12.37% |
---|---|---|
2024 | 33.42% | 1.33% |
2025 | 34.46% | 3.11% |
2026 | 34.92% | 1.33% |
2027 | 36.79% | 5.36% |
11 IDEXX Laboratories Analysts have issued a net profit forecast 2024. The average IDEXX Laboratories net profit estimate is $861m . This is 1.30% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $894m 5.21% , the lowest is $852m 0.23% .
This results in the following potential growth metrics and future Net Margins:
2023 | $825m | 25.28% |
---|---|---|
2024 | $861m | 4.32% |
2025 | $988m | 14.75% |
2026 | $1.1b | 14.54% |
2027 | $1.3b | 12.08% |
2023 | 22.54% | 15.23% |
---|---|---|
2024 | 22.18% | 1.61% |
2025 | 23.74% | 7.03% |
2026 | 24.97% | 5.18% |
2027 | 26.31% | 5.37% |
11 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $10.49 . This is 1.25% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $10.90 5.21% , the lowest is $10.38 0.19% .
This results in the following potential growth metrics and future valuations:
2023 | $10.06 | 25.28% |
---|---|---|
2024 | $10.49 | 4.27% |
2025 | $12.04 | 14.78% |
2026 | $13.79 | 14.53% |
2027 | $15.46 | 12.11% |
Current | 40.27 | 3.01% |
---|---|---|
2024 | 39.76 | 1.27% |
2025 | 34.65 | 12.85% |
2026 | 30.25 | 12.70% |
2027 | 26.99 | 10.78% |
Based on analysts' sales estimates for 2024, the IDEXX Laboratories stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 9.03 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 8.85 .
This results in the following potential growth metrics and future valuations:
Current | 9.11 | 4.51% |
---|---|---|
2024 | 9.03 | 0.92% |
2025 | 8.42 | 6.72% |
2026 | 7.73 | 8.19% |
2027 | 7.27 | 5.97% |
Current | 8.93 | 3.38% |
---|---|---|
2024 | 8.85 | 0.95% |
2025 | 8.25 | 6.72% |
2026 | 7.58 | 8.19% |
2027 | 7.12 | 5.97% |
IDEXX Laboratories...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.